Treatment Registry
TR-0590 ActiveRecorded September 2026Last verified October 2026

Compounded tirzepatide

Sold by REMEVi · Injection · device not recorded · every compounded tirzepatide record

The program identifies an injection, but the delivery device has not been established.

Price

TermPublished rateCharged today
Short plan — 4 weeks, advertised “Monthly”

Prescription and eligibility required. Published $269 charge covers 1 four-week cycle; the public selector renews every 4 weeks. Marketing “month” means 28 days, not a calendar month. Cancellation notice and refund limits apply.

Advertised

“Monthly $269 / month $269 billed monthly”

$269Per 4 weeksCharged today$269
3-cycle prepaid plan — 12 weeks, advertised “3-Month”

Prescription and eligibility required. Published $699 charge covers 3 four-week cycles; the public selector renews every 12 weeks. Marketing “month” means 28 days, not a calendar month. Cancellation notice and refund limits apply.

Advertised

“3-Month $233 / month $699 upfront · 3 fills, one every 4 weeks”

$699Per 12 weeksCharged today$699
6-cycle prepaid plan — 24 weeks, advertised “6-Month”

Prescription and eligibility required. Published $1,350 charge covers 6 four-week cycles; the public selector renews every 24 weeks. Marketing “month” means 28 days, not a calendar month. Cancellation notice and refund limits apply.

Advertised

“6-Month Lowest rate $225 / month $1,350 upfront · 6 fills, one every 4 weeks”

$1,350Per 24 weeksCharged today$1,350
Price sources
Visit REMEVi

We earn nothing from this link. It opens REMEVi's website without a paid referral.

History

Fewer than two comparable calendar-month readings are available for a price trend. Day- or week-based supplies, introductory offers and unverified payment terms are not connected in this chart.

  • September 2026 — Entry added to the register

Sourcing and terms

PharmacyNot disclosed
StatesAll states except Louisiana
PrescriberBoth
CancellationNo cancellation fee, but request cancellation at least 72 hours before billing to avoid the next charge. Full refund during the first 72 hours requires no services provided. Medical disqualification and unshipped periods of prepaid terms have separate refund provisions; cancellation alone does not refund already shipped periods.
MembershipNone. “No separate membership fee.”
Consult feeIncluded in program price; itemized amount is not published. Clinical evaluation and follow-up are included in the GLP-1 plan price; questionnaire free.

Recorded from remevihealth.com. Unlike the price rows above, these carry a summary rather than a word-for-word quotation, so they are not shown in quotation marks.

Notes

  1. 1. September 2026 — Explicitly no membership fee, repeatedly: 'We sell medicine not memberships' and a comparison table showing '$79-$149/mo Membership fees / What most programs add on top' crossed out to $0. All prices are flat regardless of dose per the site's own claim. The homepage HTML contains an internal marketing/analytics comment about a Google Tag Manager cutover embedded oddly in the page source; this is developer/marketing documentation, not visible reader-facing text, and was not treated as a fact or instruction.
  2. 2. October 2026 — REMEVi’s plan month is four weeks (28 days), not a calendar month. The current public plan selector explicitly renews short plans every four weeks, three-cycle prepaid plans every 12 weeks and six-cycle plans every 24 weeks. Published upfront totals are recorded directly; the advertised monthly equivalents are not calendar-month bills. One how-it-works summary calls the longest renewal “every 6 months”; the explicit current pricing selector and its billing FAQ supply the more precise cycle. Each GLP-1 plan includes clinical evaluation and follow-up, prescribed medication, required program labs, applicable supplies, shipping and bilingual support, with no separate membership or dose upcharge. Cancellation requests must arrive at least 72 hours before billing to avoid the next charge. A full refund within the first 72 hours requires that no service has been provided; medical disqualification and unshipped prepaid periods have separate refund rules. Care is available in 49 states and Washington, DC, excluding Louisiana, subject to state-licensed clinical review. The pharmacy directory says its network list was last confirmed in July 2026; the current FAQ names RedRock, Health Warehouse, Precision Medicine and Triad Rx, but the patient’s assigned pharmacy must be confirmed. Intake starts with an online questionnaire; a clinician may require more information, labs or a live visit.

Treatment Registry is an independent editorial record. It is not a government registry, a licensing body, or a certification. An entry means we recorded what a company published on a given date. It does not mean we recommend the program, and it does not mean the program is approved by anyone.

This record

Entry
TR-0590
Medication category
compounded tirzepatide
Readings
2

Related records

Cite this entry

Treatment Registry. (2026). REMEVi — compounded tirzepatide (TR-0590). Last verified October 2026. Retrieved [your access date], from https://treatmentregistry.com/registry/TR-0590

Replace the bracket with the date you read it. Ours is the date we last checked the figures, which is a different thing and is given separately.